Kyverna seeks $182M IPO as biotech runs multiple autoimmune CAR-T trials
Kyverna Therapeutics aims to be the fifth biotech to IPO in 2024 as the autoimmune CAR-T cell therapy maker sets its sights on $182 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
